Misclassified Alcohol-related Liver Disease is Common in Presumed Metabolic Dysfunction-associated Steatotic Liver Disease and Highly Increases Risk for Future Cirrhosis

被引:20
|
作者
Nasr, Patrik [1 ,2 ]
Wester, Axel [2 ]
Ekstedt, Mattias [1 ]
Strandberg, Rickard [2 ]
Kechagias, Stergios [1 ]
Shang, Ying [2 ]
Widman, Linnea [2 ]
Hagstrom, Hannes [2 ,3 ]
机构
[1] Linkoping Univ, Dept Hlth Med & Caring Sci, Div Diagnost & Specialist Med, Linkoping, Sweden
[2] Karolinska Inst, Dept Med, C1 77, S-14186 Stockholm, Sweden
[3] Karolinska Univ Hosp, Dept Upper GI, Div Hepatol, Stockholm, Sweden
关键词
Alcohol-related Liver Disease; Alcohol Use Disorder; Epidemiology; MAFLD; MetALD; NAFLD; CONSUMPTION; PHOSPHATIDYLETHANOL; BLOOD; PETH; FIBROSIS; MARKER;
D O I
10.1016/j.cgh.2024.01.006
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: Alcohol overconsumption is a risk factor for disease progression in patients with presumed metabolic dysfunction-associated steatotic liver disease (MASLD). How commonly this occurs and how it affects progression to major adverse liver outcomes (MALOs) is not well known. METHODS: We did a register-based cohort study, including all patients with a diagnosis of MASLD in Sweden between 1987 and 2020. Patients were strati fi ed on co-occurrence of diagnoses of alcohol-related liver disease (ALD) or alcohol use disorder (AUD) prior to MASLD diagnosis. Incident MALOs were derived from national registers. Cox regression was used to calculate hazard ratios (HRs) for incident MALO. RESULTS: A total of 15,107 patients with MASLD were identi fi ed. The median age was 55 years, and 52% were female. Of the patients, 1843 (12%) had a prior diagnosis of ALD or AUD. During followup, a further 787 patients (5.2%) received a diagnosis of ALD or AUD. Patients with previous ALD or AUD diagnoses at or before baseline had considerably higher rates of MALOs compared with patients without (19.5% vs 7.8%; adjusted HR, 3.12; 95% con fi dence interval, 2.74 - 3.55). Acquiring an ALD or AUD diagnosis after MASLD diagnosis was associated with higher rates of MALOs (adjusted HR, 5.81; 95% con fi dence interval, 4.90 - 6.88). CONCLUSIONS: ALD or AUD is commonly diagnosed prior to or after MASLD diagnosis. Such patients have considerably higher rates of progression to MALOs. Correctly separating between MASLD and ALD is vital to assess prognosis.
引用
收藏
页码:1048 / 1057.e2
页数:12
相关论文
共 50 条
  • [1] Epidemiology of metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-related liver disease (ALD)
    Wong, Robert J.
    METABOLISM AND TARGET ORGAN DAMAGE, 2024, 4 (04):
  • [2] Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor
    Platek, Anna E.
    Szymanska, Anna
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2023, 9 (03) : 187 - 192
  • [3] Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review
    Zheng, Haixiang
    Sechi, Leonardo Antonio
    Navarese, Eliano Pio
    Casu, Gavino
    Vidili, Gianpaolo
    CARDIOVASCULAR DIABETOLOGY, 2024, 23 (01)
  • [4] Higher Adherence to the Mediterranean Diet Is Associated with a Lower Risk of Steatotic, Alcohol-Related, and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Analysis
    Lee, Ji Yae
    Kim, Sue
    Lee, Yaeji
    Kwon, Yu-Jin
    Lee, Ji-Won
    NUTRIENTS, 2024, 16 (20)
  • [5] Metabolic dysfunction-associated steatotic liver disease and atherosclerosis
    Castillo-Nunez, Yulino
    Almeda-Valdes, Paloma
    Gonzalez-Galvez, Guillermo
    Arechavaleta-Granell, Maria del Rosario
    CURRENT DIABETES REPORTS, 2024, 24 (07) : 158 - 166
  • [6] Metabolic Dysfunction-Associated Steatotic Liver Disease
    Ali, Sajjadh M. J.
    Lai, Michelle
    ANNALS OF INTERNAL MEDICINE, 2025, 178 (01) : ITC1 - ITC17
  • [7] Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease with Increased Alcohol Intake Increase the Risk of Developing Hepatocellular Carcinoma and Incident or Decompensated Cirrhosis: A Korean Nationwide Study
    Kim, Gi-Ae
    Jeong, Seogsong
    Jang, Heejoon
    Lee, Dong Hyeon
    Joo, Sae Kyung
    Kim, Won
    LIVER CANCER, 2024, 13 (04) : 426 - 437
  • [8] Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study
    Yun, Byungyoon
    Park, Heejoo
    Ahn, Sang Hoon
    Oh, Juyeon
    Kim, Beom Kyung
    Yoon, Jin-Ha
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2025, 120 (02): : 410 - 419
  • [9] Metabolic dysfunction-associated steatotic liver disease: A silent pandemic
    Samanta, Arghya
    Sen Sarma, Moinak
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (04)
  • [10] Elucidating cuproptosis in metabolic dysfunction-associated steatotic liver disease
    Li, Yamei
    Qi, Ping
    Song, Si -Yuan
    Wang, Yiping
    Wang, Hailian
    Cao, Peng
    Liu, Yu 'e
    Wang, Yi
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 174